Heron Therapeutics, Inc. (0J4V.L)
USD 1.62
(0.31%)
USD 1.62
(0.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 145.07 Million USD | 6.22% |
| 2022 | 142.11 Million USD | 106.1% |
| 2021 | 68.95 Million USD | 185.63% |
| 2020 | -80.52 Million USD | -54.54% |
| 2019 | -52.1 Million USD | -91.13% |
| 2018 | -27.26 Million USD | 76.48% |
| 2017 | -115.89 Million USD | -393.44% |
| 2016 | 39.49 Million USD | 154.14% |
| 2015 | -72.95 Million USD | -2.65% |
| 2014 | -71.07 Million USD | 0.26% |
| 2013 | -71.26 Million USD | -33.19% |
| 2012 | -53.5 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 158.72 Million USD | 5.15% |
| 2024 Q2 | 155.84 Million USD | 1.01% |
| 2023 Q2 | 142.66 Million USD | 9.88% |
| 2023 Q1 | 129.83 Million USD | -8.64% |
| 2023 Q3 | 145.13 Million USD | 1.74% |
| 2023 Q4 | 150.95 Million USD | 4.0% |
| 2023 FY | 150.95 Million USD | 6.22% |
| 2022 Q2 | 109.9 Million USD | 7.65% |
| 2022 Q1 | 102.09 Million USD | 48.06% |
| 2022 FY | 142.11 Million USD | 106.1% |
| 2022 Q4 | 142.11 Million USD | 32.12% |
| 2022 Q3 | 107.56 Million USD | -2.12% |
| 2021 Q4 | 68.95 Million USD | 1298.66% |
| 2021 Q3 | 4.93 Million USD | 118.95% |
| 2021 FY | 68.95 Million USD | 185.63% |
| 2021 Q1 | -35.31 Million USD | 57.72% |
| 2021 Q2 | -26.01 Million USD | 26.33% |
| 2020 Q1 | -80.64 Million USD | -49.25% |
| 2020 FY | -80.52 Million USD | -54.54% |
| 2020 Q2 | -58.44 Million USD | 27.52% |
| 2020 Q3 | -73.2 Million USD | -25.25% |
| 2020 Q4 | -83.52 Million USD | -14.09% |
| 2019 Q4 | -54.03 Million USD | -22.88% |
| 2019 Q3 | -43.97 Million USD | -19.79% |
| 2019 Q2 | -36.7 Million USD | -430.66% |
| 2019 Q1 | -6.91 Million USD | 74.63% |
| 2019 FY | -52.1 Million USD | -91.13% |
| 2018 FY | -27.26 Million USD | 76.48% |
| 2018 Q4 | -27.26 Million USD | 45.03% |
| 2018 Q3 | -49.59 Million USD | 78.42% |
| 2018 Q2 | -229.82 Million USD | -1199.82% |
| 2018 Q1 | -17.68 Million USD | 84.74% |
| 2017 Q3 | -37.04 Million USD | -1759.59% |
| 2017 FY | -115.89 Million USD | -393.44% |
| 2017 Q2 | -1.99 Million USD | 93.45% |
| 2017 Q1 | -30.41 Million USD | -177.01% |
| 2017 Q4 | -115.89 Million USD | -212.88% |
| 2016 Q3 | 7.09 Million USD | 111.94% |
| 2016 Q2 | -59.38 Million USD | 9.51% |
| 2016 Q4 | 39.49 Million USD | 456.92% |
| 2016 FY | 39.49 Million USD | 154.14% |
| 2016 Q1 | -65.62 Million USD | 10.05% |
| 2015 FY | -72.95 Million USD | -2.65% |
| 2015 Q1 | -53.8 Million USD | 24.3% |
| 2015 Q4 | -72.95 Million USD | 51.66% |
| 2015 Q3 | -150.92 Million USD | 11.02% |
| 2015 Q2 | -169.62 Million USD | -215.24% |
| 2014 FY | -71.07 Million USD | 0.26% |
| 2014 Q2 | -103.7 Million USD | -84.17% |
| 2014 Q3 | -84.76 Million USD | 18.27% |
| 2014 Q4 | -71.07 Million USD | 16.15% |
| 2014 Q1 | -56.31 Million USD | 20.98% |
| 2013 Q3 | -21.7 Million USD | 36.33% |
| 2013 Q2 | -34.09 Million USD | 24.4% |
| 2013 Q4 | -71.26 Million USD | -228.26% |
| 2013 Q1 | -45.1 Million USD | 15.71% |
| 2013 FY | -71.26 Million USD | -33.19% |
| 2012 Q4 | -53.5 Million USD | 0.0% |
| 2012 FY | -53.5 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 266.532% |
| Dynavax Technologies Corporation | 106.63 Million USD | -36.049% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 532.714% |
| Perrigo Company plc | 3.32 Billion USD | 95.633% |
| Illumina, Inc. | 1.21 Billion USD | 88.05% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.459% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 227.385% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 98.238% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 98.871% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 635.336% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1918.589% |
| Waters Corporation | 1.96 Billion USD | 92.6% |
| Biogen Inc. | 6.28 Billion USD | 97.693% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2143.324% |
| Evolus, Inc. | 63.7 Million USD | -127.72% |
| Adicet Bio, Inc. | -142 Million USD | 202.16% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1709.095% |
| bluebird bio, Inc. | 108.57 Million USD | -33.623% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 68.372% |
| FibroGen, Inc. | 56.76 Million USD | -155.564% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 87.33% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1982.009% |
| Homology Medicines, Inc. | 18.43 Million USD | -686.874% |
| Geron Corporation | 14.76 Million USD | -882.833% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 90.849% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 26.753% |
| Myriad Genetics, Inc. | 88.1 Million USD | -64.672% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 367.392% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 230.227% |
| Zoetis Inc. | 4.76 Billion USD | 96.953% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 1540.532% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 93.085% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 61.696% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.517% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1095.581% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 86.239% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -354.998% |
| Verastem, Inc. | -37.27 Million USD | 489.173% |
| Nektar Therapeutics | 210.24 Million USD | 30.995% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 172.603% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 494.185% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 85.019% |
| OPKO Health, Inc. | 230.68 Million USD | 37.11% |
| Exelixis, Inc. | -73.05 Million USD | 298.598% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 18.175% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 207.146% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 196.062% |
| uniQure N.V. | -102.95 Million USD | 240.918% |
| Imunon, Inc. | -4.69 Million USD | 3187.201% |
| Blueprint Medicines Corporation | 702.83 Million USD | 79.358% |
| Insmed Incorporated | 721.62 Million USD | 79.896% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 89.494% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 564.734% |
| TG Therapeutics, Inc. | 17.86 Million USD | -712.205% |
| Incyte Corporation | -3.17 Billion USD | 104.569% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 81.056% |